Press Releases
CIT launches LeadScreen (TM), a new range of fast, cost-effective services for drug candidate selection
CIT, a leading European non-clinical CRO specialized in health and safety research, announces today a new range of fast and economical services to meet the...
Press Releases
Ken Jones, COO Europe, Astellas joins GSK, Shire, Takeda and Bausch & Lomb on value based selling panel session
With one week to go SFE Europe shows no sign of slowing down. With over 550 confirmed attendees and an a 80% ratio from within...
Press Releases
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma
Roche announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal...
Press Releases
Novartis completes acquisition of majority stake in Zhejiang Tianyuan
Novartis announced that it completed the transaction to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. This acquisition...
Press Releases
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival
Bristol-Myers Squibb Company announced that a clinical trial -- known as study 024 -- of its investigational compound ipilimumab has met the primary endpoint of...
Press Releases
PharmaDiagnostics announces three new coupling methods for its SoPRano(TM) label-free platform
PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of three...
Press Releases
Provepharm receives favorable EMA Review of its methylthioninium chloride Proveblue
Provepharm, a start-up specialized in the development of pharmaceutical applications, announces today that, following a one-year centralized review procedure, the European Medicines Agency’s Committee for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.